Abstract:Many clinical studies have shown that induction chemotherapy followed by concurrent chemoradiotherapy improved the survival of locally advanced nasopharyngeal carcinoma (NPC). However, it is still unknown that which induction chemotherapy regimen is the optimal choice. This study focused on the comparison of efficacy and toxicities between induction chemotherapy regimen TPF and GP in locally advanced NPC. Between January 2008 and July 2015, patients with locally advanced NPC (clinical stage III-IVb) were retrospectively analyzed. Inclusion criteria were as follows: (1) pathologically confirmed NPC; (2) clinical stage III-IVb according to the 7th edition of the American Joint Committee on Cancer (AJCC) stage criteria; (3) receiving either TPF regimen plus CCRT or GP regimen plus CCRT; (4) radiotherapy was performed using intensity modulated radiation therapy (IMRT). Exclusion criteria were as follows: (1) patients receiving adjuvant chemotherapy; (2) patients with other malignant diseases. The primary endpoint was overall survival (OS). The Secondary endpoints included progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS). The Kaplan-Meier survival curves and log-rank test were used to evaluate the OS, PFS, LRFS, and DMFS of the two groups. Univariate and multivariate analyses were applied to identify the independent prognostic factors. Chi-square test was performed to compare the toxic effects between the two groups. A total of 80 patients treated with TPF regimen plus CCRT and 80 with GP regimen plus CCRT were eligible for this study. After a median follow-up of 47 months (range 8–97months), no differences were observed between the two groups in terms of 3-year OS (86.1% vs. 94.8%, p = 0.123), PFS (81.1% vs. 90.8%, p = 0.224), DMFS (82.3% vs. 94.1%, p = 0.087), or LRFS (93.6% vs.96.1%, p = 0.794). The results of the multivariate Cox proportional hazard analysis showed that the treatment group was not an independent prognostic factor for OS (HR 2.341; 95% CI 0.878–6.241; p = 0.089), PFS (HR 1.814; 95% CI 0.815–4.036; p=0.145), DMFS (HR 2.343; 95%CI 0.942–5.830; p = 0.067), or LRFS (HR 1.243; 95% CI 0.377–4.103; p = 0.721). Clinical stage was an independent prognostic factor affecting OS (HR 0.198; 95 %CI 0.040–0.975; p = 0.046) and PFS (HR 0.224; 95 %CI 0.062–0.810; p = 0.023).There was significant difference in III-IV hepatic toxicity between the two groups (0 vs. 18.6%, p=0.000). No significant differences were observed in bone marrow suppression and kidney dysfunction between the two arms. GP induction chemotherapy plus CCRT achieved similar survival outcomes to those with TPF induction chemotherapy for locally advanced NPC. However, GP regimen increased grade 3–4 hepatic dysfunction compared with TPF induction chemotherapy. More prospective clinical trials are needed to determine the most effective induction chemotherapy regimen for locally advanced NPC.

Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma

Assessment of Induction Chemotherapy Regimen TPF Versus GP Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study

Gemcitabine/Cisplatin versus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in locally advanced nasopharyngeal carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study

Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma

Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China

Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety of the TPC Regimen Compared to GP and TPF

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma

Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma

Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level

Comparison of Two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma

Comparisons of tumor volume reduction and early survivals between regimes of gemcitabine plus cisplatin and paclitaxel plus cisplatin for induction chemotherapy in patients with naso-pharyngeal cancer

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens

Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching